期刊
BREAST JOURNAL
卷 27, 期 4, 页码 359-362出版社
WILEY-HINDAWI
DOI: 10.1111/tbj.14204
关键词
CDK4; 6 inhibitors; Covid-19; HR positive; HER2 negative metastatic breast cancer
The COVID-19 pandemic has led to significant changes in the management of cancer patients worldwide, including reduced screening, delayed surgeries and radiotherapy, as well as dose reductions or delays in systemic therapy administration, such as CDK 4/6 inhibitors.
Substantial changes in the management of cancer patients have been required worldwide in response to the COVID-19 pandemic. Beyond the due details on the primitive cancer site and setting at diagnosis, these latter adaptions are most commonly exemplified by a significant reduction in the screening of asymptomatic subjects, delays in elective surgery and radiotherapy for primary tumors, and dose reductions and/or delays in systemic therapy administration. Advanced breast cancer patients with hormonal receptor positive, HER2 negative tumors are usually treated with endocrine therapy combined with CDK 4/6 inhibitors as first- and second-line treatment. During the pandemic, experts' recommendations have suggested the omission or delay of CDK 4/6 inhibitors delivery, or a careful evaluation of their real need due to the hypothesized increased risk of SARS-Cov-2 infection and disease possibly related to neutropenia. The inherent literature is sparse and inconsistent. We herein present data on the use of CDK 4/6 inhibitors during the pandemic. The evidence reported punctually reflects the experience matured at our Institution, a comprehensive cancer centre, on the topic of interest.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据